Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$1.00
-$0.03(-0.72%)
At close: 4:00 PM EST
$1.00
-$0.03(-0.72%)
Day’s Range― - ―
52-Week Range$0.55 - $2.22
Previous CloseN/A
Volume2.88K
Average Volume (3M)55.77K
Market Cap
$8.85M
Enterprise Value-$41.40M
Total Cash (Recent Filing)$46.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Aug 06, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding12,382,776
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-4.68
Enterprise Value/Revenue-350.53
Enterprise Value/Gross Profit23.01
Enterprise Value/Ebitda3.47
Forecast
1Y Price Target
$4.30Price Target Upside330.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$1.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtAprea's lack of debt materially reduces refinancing and interest-rate risk, providing durable financial flexibility as it advances clinical programs. This structural advantage lengthens optionality for funding R&D or partnering without immediate pressure from fixed interest obligations.
Fresh Financing Extends RunwayThe $30M oversubscribed placement meaningfully extends cash runway into Q1 2028, enabling planned expansion of the APR-1051 Phase 1 study and dose escalation. This reduces near-term financing urgency and supports executing clinical milestones that can de-risk the lead program.
Clinical Progress For Lead ProgramObservable partial responses and tolerability in APR-1051 patients strengthen the company's biomarker-driven oncology strategy. Durable clinical signals can justify expanded enrollment, partnerships, or further investment, increasing the likelihood of long-term pipeline value capture if replicated in larger cohorts.
Bears Say
Persistent Cash BurnOperating cash flow and free cash flow are consistently negative, reflecting ongoing cash burn despite some reduction versus prior years. Sustained negative cash generation means Aprea will remain dependent on fresh capital or partnerships to fund operations absent meaningful revenue or milestone inflows.
Ongoing Losses & Volatile RevenueThe company records persistent net losses and a sharp TTM revenue decline (~58%), highlighting lack of recurring commercial revenue. This structural deficit limits margin sustainability and increases reliance on R&D outcomes and financing to achieve longer-term profitability.
Capital Structure / Listing Flexibility RiskAuthorization for a reverse split signals enduring share-price and listing compliance pressures; combined with prior equity issuance and warrants, it underscores dilution and capital-raising constraints. This structural governance tool reflects ongoing challenges in maintaining investor confidence and capital access.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $2.22 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $8.85M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.008.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 12,382,776 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$4.30
▲(330.00% Upside)
Technical Analysis
Ownership Overview
6.50% Insiders
0.86% Mutual Funds
15.36% Other Institutional Investors
77.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---